Mengmeng Niu

9PUBLICATIONS
13CO-AUTHORS
Molecular targetsCancer diagnosisPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 29, 2026
Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan.

Jing Xu, Jing Liu, Yang Liu

|Jan 02, 2025
Mitochondrial-cytochrome c oxidase II promotes glutaminolysis to sustain tumor cell survival upon glucose deprivation.

Yong Yi, Guoqiang Wang, Wenhua Zhang

|Feb 27, 2024
Hypoxia-activated XBP1s recruits HDAC2-EZH2 to engage epigenetic suppression of ΔNp63α expression and promote breast cancer metastasis independent of HIF1α.

Hu Chen, Shuhan Yu, Ruidong Ma

|Dec 22, 2023
FBXO3 stabilizes USP4 and Twist1 to promote PI3K-mediated breast cancer metastasis.

Jing Xu, Rongtian Guo, Nasi Wen

|Oct 13, 2023
USP36 stabilizes nucleolar Snail1 to promote ribosome biogenesis and cancer cell survival upon ribotoxic stress.

Kewei Qin, Shuhan Yu, Yang Liu

|Dec 02, 2022
FBXL2 promotes E47 protein instability to inhibit breast cancer stemness and paclitaxel resistance.

Fengtian Li, Mengmeng Niu, Kewei Qin

Pageof 2

Frequent Collaborators

6 joint publications

Zhi-Xiong Jim Xiao

5 joint publications

Hu Chen

5 joint publications

Yong Yi

3 joint publications

Yang Cao